TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20098295

Group type: EXPERIMENTAL
Intervention: Carraguard vaginal gel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methylcellulose placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: No product
Number of subjects: 60
Study: 18038224

Group type: EXPERIMENTAL
Intervention: 100 mg quetiapine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 100 mg quetiapine (after 5 days of daily intake)
Number of subjects: 15
Study: 15951127

Group type: EXPERIMENTAL
Intervention: Two-part treatment intervention aimed to reduce long-term benzodiazepine use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients still using benzodiazepines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients who had received additional tapering off
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients who had quit benzodiazepine use after one of the two interventions
Number of subjects: 0
Study: 12517654

Group type: EXPERIMENTAL
Intervention: Oil-soluble contrast medium
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no additional contrast medium)
Number of subjects: 56
Study: 11120733

Group type: EXPERIMENTAL
Intervention: Vitamin B6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ginger
Number of subjects: 0
Study: 9259652

Group type: COMPARATOR
Intervention: 160 mg aspirin
Number of subjects: 8803

Group type: EXPERIMENTAL
Intervention: 3 mg warfarin with 80 mg aspirin
Number of subjects: 8803

Group type: EXPERIMENTAL
Intervention: 1 mg warfarin with 80 mg aspirin
Number of subjects: 8803
Study: 8272491

Group type: EXPERIMENTAL
Intervention: Surgeons wearing sterile gloves
Number of subjects: 124

Group type: COMPARATOR
Intervention: Surgeons wearing nonsterile, but clean gloves
Number of subjects: 124
Study: 3614964

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3 mg in 10 ml glucose solution)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Morphine (3 mg in 10 ml glucose solution)
Number of subjects: 12
Study: 30572548

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT) combined with conventional rehabilitation therapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional rehabilitation therapy only
Number of subjects: 82
Study: 27206212

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1μg/kg 10min before anesthesia induction, maintain dose 0.4μg/(kg/h))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 60
Study: 24406474

Group type: EXPERIMENTAL
Intervention: Morning-only polyethylene glycol (PEG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Split-dose polyethylene glycol (PEG)
Number of subjects: 120
Study: 22414509

Group type: EXPERIMENTAL
Intervention: Catalase‐based neutralizer gel applied for three minutes
Number of subjects: 30

Group type: COMPARATOR
Intervention: 10% carbamide peroxide bleaching agent
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bleached specimens with catalase‐based gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonbleached negative control specimens
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bleached positive control specimens
Number of subjects: 30
Study: 20708510

Group type: EXPERIMENTAL
Intervention: Epidural 0.5% lidocaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epidural 1% lidocaine
Number of subjects: 40
Study: 18093572

Group type: EXPERIMENTAL
Intervention: Appraisals of intrusive thoughts (personal significance rating)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Appraisals of socially unacceptable thoughts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relation of appraisals to OC symptoms
Number of subjects: 0
Study: 15990754

Group type: EXPERIMENTAL
Intervention: Brachytherapy (90Sr/90Y beta-radiation)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Placebo (nonactive source train)
Number of subjects: 476
Study: 12848635

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 20 mg rabeprazole
Number of subjects: 27
Study: 10096266

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Rofecoxib 500 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 8769696

Group type: EXPERIMENTAL
Intervention: IFN-α
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: IFN-α/ara-C
Number of subjects: 139
Study: 8425237

Group type: EXPERIMENTAL
Intervention: Alprazolam 1 mg
Number of subjects: 65

Group type: COMPARATOR
Intervention: Hydroxyzine 75 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Comparison of sedation and memory test
Number of subjects: 65
Study: 2949584

Group type: EXPERIMENTAL
Intervention: PN 200-110 (isradipine) combined with pindolol
Number of subjects: 61
Study: 29920440

Group type: EXPERIMENTAL
Intervention: Active rTMS (n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham rTMS (n=15)
Number of subjects: 30
Study: 27741334

Group type: EXPERIMENTAL
Intervention: Ingenol mebutate 0.05% gel
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference skin
Number of subjects: 24
Study: 24946835

Group type: EXPERIMENTAL
Intervention: Low right atrial septal (LRAS) pacing
Number of subjects: 102

Group type: COMPARATOR
Intervention: Right atrial appendage (RAA) pacing
Number of subjects: 102
Study: 22705219

Group type: EXPERIMENTAL
Intervention: Cone beam computed tomography (CBCT)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Dental panoramic radiography (PAN)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: CBCT
Number of subjects: 79

Group type: COMPARATOR
Intervention: PAN
Number of subjects: 79
Study: 20540264

Group type: EXPERIMENTAL
Intervention: Anterior subcutaneous transposition
Number of subjects: 66

Group type: COMPARATOR
Intervention: Anterior submuscular transposition
Number of subjects: 66
Study: 19326771

Group type: EXPERIMENTAL
Intervention: Sobrietol (amethystic product)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 2
Study: 15736108

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg bid)
Number of subjects: 0
Study: 12773445

Group type: EXPERIMENTAL
Intervention: HP hMG
Number of subjects: 100
Study: 10813592

Group type: EXPERIMENTAL
Intervention: Exercise ventilation and cardiac output in prematurely born children
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Submaximal exercise with measurement of cardiac output (indirect [CO2] Fick)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Physiologic dead space normalized for body weight
Number of subjects: 32

Group type: COMPARATOR
Intervention: Heart rate-VO2 relationship and stroke volume
Number of subjects: 32
Study: 9014745

Group type: EXPERIMENTAL
Intervention: High-dose melphalan with G-CSF-primed unprocessed whole blood
Number of subjects: 30

Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 30
Study: 2061776

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 6760969

Group type: EXPERIMENTAL
Intervention: 24 hours of cefuroxime prophylaxis (0.75 gm 30 to 60 minutes before surgery and at 8 hours and 16 hours after surgery)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Five days of cefuroxime prophylaxis (0.75 gm three times a day, the first dose being given postoperatively)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No prophylactic antibiotics (control group)
Number of subjects: 60
Study: 31322914

Group type: EXPERIMENTAL
Intervention: Immunosuppression, anti-arrhythmic medications, heart failure medications, device therapy, ablation therapy, heart transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Screening for cardiac sarcoidosis
Number of subjects: 0
Study: 29330636

Group type: EXPERIMENTAL
Intervention: CT-P6 (6 mg/kg, 90 min intravenous infusion)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Reference trastuzumab (6 mg/kg, 90 min intravenous infusion)
Number of subjects: 70
Study: 26589462

Group type: EXPERIMENTAL
Intervention: Backboard
Number of subjects: 43

Group type: COMPARATOR
Intervention: No backboard
Number of subjects: 43
Study: 25403211

Group type: EXPERIMENTAL
Intervention: Telephone-based peer-support intervention (IG)
Number of subjects: 337
Study: 22088571

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19445704

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Planned early delivery at 37-38 weeks
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Trial recruitment rate
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Spectrum of disease among recruits and non-recruits
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Compliance with treatment allocations
Number of subjects: 4500
Study: 17784946

Group type: EXPERIMENTAL
Intervention: Maximal intervention group receiving prevention consultations by GP with personalized feedback and intensive support for health behaviour change.
Number of subjects: 350

Group type: COMPARATOR
Intervention: Minimal intervention group receiving prevention consultations using a cardiovascular risk calculator and general feedback.
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Maximal intervention group
Number of subjects: 350

Group type: COMPARATOR
Intervention: Minimal intervention group
Number of subjects: 350
Study: 15097246

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (20 mg/day for 4 weeks)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 12234947

Group type: EXPERIMENTAL
Intervention: DL‐alpha‐tocopherol 400 IU per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9652433

Group type: EXPERIMENTAL
Intervention: Standard dose (1.6 x 10(8) cfu)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: High dose (3.2 x 10(8) cfu)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Very low dose (1.6 x 10(5) cfu)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Low dose (3.2 x 10(6) cfu)
Number of subjects: 76
Study: 8205868

Group type: EXPERIMENTAL
Intervention: Twice-daily regimen A: 500 micrograms in the morning and at bedtime
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Single dose regimen B: 1,000 micrograms in the late afternoon
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Single dose regimen C: 1,000 micrograms at bedtime
Number of subjects: 42
Study: 2643914

Group type: EXPERIMENTAL
Intervention: Continuous infusion of zidovudine at various rates (0.5, 0.9, 1.4, 1.8 mg/kg body weight per hour)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Continuous infusion of zidovudine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Bolus administration of zidovudine (80 mg/m2 over 1 hour)
Number of subjects: 21
Study: 936954

Group type: EXPERIMENTAL
Intervention: 2 g cephalothin at the induction of anesthesia and another 2 g, 5 and 10 hours after the primary infusion (treatment group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group remained untreated
Number of subjects: 0
Study: 30395961

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate and carboxymethyl cellulose solution (HA‐CMC sol)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Corticosteroids and local anesthetics (control group)
Number of subjects: 44
Study: 28740125

Group type: EXPERIMENTAL
Intervention: Dietary FA intervention for 12 weeks
Number of subjects: 442

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Elevated plasma n-3 PUFA
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: High proportion of plasma C16:0
Number of subjects: 442
Study: 26156665

Group type: EXPERIMENTAL
Intervention: Indwelling drain (group A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No indwelling drain (group B)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Indwelling drain (group A) and No indwelling drain (group B)
Number of subjects: 43
Study: 23819600

Group type: EXPERIMENTAL
Intervention: Brief educational intervention in cardiovascular prevention
Number of subjects: 75000

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 75000
Study: 21767016

Group type: EXPERIMENTAL
Intervention: Appearance-related intervention (plus usual care)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 70
Study: 18438228

Group type: EXPERIMENTAL
Intervention: Experimental energy patches
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 41
Study: 16406076

Group type: EXPERIMENTAL
Intervention: Contact diode laser myringotomy (CDLM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Myringotomy with tube insertion (M&T)
Number of subjects: 30
Study: 14632856

Group type: COMPARATOR
Intervention: Anticholinergic treatment (group 1) for 6 months
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Surgery for SUI (group 2)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (group 3) with pure SUI
Number of subjects: 75
Study: 10704958

Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9067537

Group type: EXPERIMENTAL
Intervention: Sensitization with DPCP on non-UV-exposed normal skin
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sensitization with DPCP on skin exposed to three MED of UVB radiation
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sensitization with DPCP on skin exposed to three MED of UVA radiation
Number of subjects: 46

Group type: COMPARATOR
Intervention: No sensitization
Number of subjects: 46
Study: 8180325

Group type: EXPERIMENTAL
Intervention: Reviparin-sodium (1,750 anti-Xa IU once a day in the morning followed by placebo in the evening for at least 6 days)
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Unfractionated heparin (5,000 U twice a day for at least 6 days)
Number of subjects: 1351
Study: 3724174

Group type: EXPERIMENTAL
Intervention: L-thyroxine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonthyroxine treatment (control group)
Number of subjects: 0
Study: 29244111

Group type: EXPERIMENTAL
Intervention: Higher baseline serum albumin (per 1 g/dL)
Number of subjects: 4576

Group type: EXPERIMENTAL
Intervention: Higher baseline serum albumin
Number of subjects: 4576
Study: 27270900

Group type: EXPERIMENTAL
Intervention: High-intensity stretching (no-MVC session)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-intensity stretching (MVC session)
Number of subjects: 11
Study: 24457527

Group type: EXPERIMENTAL
Intervention: Diet plus aerobic exercise (D/Ex)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Diet only (DO)
Number of subjects: 75
Study: 22560101

Group type: EXPERIMENTAL
Intervention: 100% oxygen via nonrebreather mask at 15 L/min for 15 minutes
Number of subjects: 204

Group type: COMPARATOR
Intervention: Room air via nonrebreather mask for 15 minutes (placebo)
Number of subjects: 204
Study: 20530280

Group type: EXPERIMENTAL
Intervention: 1 year of trastuzumab treatment
Number of subjects: 3401

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 3401
Study: 18845993

Group type: EXPERIMENTAL
Intervention: Whole Breast Irradiation (WBI)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation (PBI)
Number of subjects: 29
Study: 16189633

Group type: EXPERIMENTAL
Intervention: Oral calcitriol pulse therapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intravenous OCT
Number of subjects: 46

Group type: COMPARATOR
Intervention: Intravenous OCT in refractory patients
Number of subjects: 46
Study: 12505809

Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 175

Group type: COMPARATOR
Intervention: Nonobese patients
Number of subjects: 175
Study: 10955749

Group type: EXPERIMENTAL
Intervention: 85% exercise load
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 95% exercise load
Number of subjects: 20
Study: 8860065

Group type: EXPERIMENTAL
Intervention: beta‐interferon (3 x 10(6) IM for 2 months and consecutive 6 x 10(6) IM for 10 months) every second evening
Number of subjects: 26

Group type: COMPARATOR
Intervention: aspecific treatment
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: beta‐interferon
Number of subjects: 26
Study: 1632114

Group type: EXPERIMENTAL
Intervention: 10 mg pirenzepine i.v.
Number of subjects: 12

Group type: COMPARATOR
Intervention: 2 ml of 0.9% NaCl i.v. (Control)
Number of subjects: 12
Study: 6235908

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) + streptozotocin (Stz)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) + Methyl‐CCNU (MeCCNU)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Methyl‐CCNU alone
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Streptozotocin alone
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) for bile duct cancer
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) + streptozotocin (Stz) for bile duct cancer
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) + Methyl‐CCNU (MeCCNU) for bile duct cancer
Number of subjects: 87
Study: 29630791

Group type: EXPERIMENTAL
Intervention: 0.454% w/w stannous fluoride dentifrice
Number of subjects: 238

Group type: COMPARATOR
Intervention: Sodium monofluorophosphate (SMFP) dentifrice
Number of subjects: 238
Study: 26951644

Group type: EXPERIMENTAL
Intervention: Standard care plus pain advice from an independent investigator
Number of subjects: 280

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 280
Study: 25391190

Group type: EXPERIMENTAL
Intervention: Human milk fortified with human milk fortifier (HMF)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Post discharge formula (PDF)
Number of subjects: 33
Study: 22453865

Group type: EXPERIMENTAL
Intervention: First-generation antipsychotic drugs (FGAs) - perphenazine and haloperidol
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotic drugs (SGAs) - olanzapine and clozapine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Healthy controls (matched for age and gender)
Number of subjects: 84
Study: 20490908

Group type: EXPERIMENTAL
Intervention: Non-occupational post-exposure prophylaxis (nPEP)
Number of subjects: 4295

Group type: COMPARATOR
Intervention: Control group (non-nPEP users)
Number of subjects: 4295
Study: 18385918

Group type: EXPERIMENTAL
Intervention: Calcitonin 0.15 mg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Calcitonin 0.4 mg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Calcitonin 1 mg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Calcitonin 2.5 mg
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 15999421

Group type: EXPERIMENTAL
Intervention: Topical application of hyaluronic acid (HA) 5 times daily for 1 week
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study: 12198664

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily starting one week before transplantation until week 52 after transplantation (group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No antiviral therapy to HBV (group 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lamivudine (group 1)
Number of subjects: 20
Study: 9801852

Group type: EXPERIMENTAL
Intervention: Bisphosphonates (specifically pamidronate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: First-generation bisphosphonates (etidronate and clodronate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-generation bisphosphonates (pamidronate)
Number of subjects: 0
Study: 8657501

Group type: EXPERIMENTAL
Intervention: Supplementation with carnitine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal weight newborns
Number of subjects: 15
Study: 2114350

Group type: EXPERIMENTAL
Intervention: Esophageal tamponade (n = 52)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Vasopressin/nitroglycerin infusion (n = 56)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 108
Study: 111704

Group type: EXPERIMENTAL
Intervention: Trifluorothymidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adenine arabinoside
Number of subjects: 0
Study: 31116172

Group type: EXPERIMENTAL
Intervention: Virtual Standardized Patient (VSP) cases
Number of subjects: 14
Study: 27878809

Group type: EXPERIMENTAL
Intervention: Telephone-assisted self-help (TASH) intervention
Number of subjects: 103

Group type: COMPARATOR
Intervention: Routine clinical care (including continued medication)
Number of subjects: 103
Study: 25961767

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (74 caregivers)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) (74 caregivers)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 148
Study: 24001627

Group type: EXPERIMENTAL
Intervention: Supervised aerobic music exercise
Number of subjects: 146

Group type: COMPARATOR
Intervention: Different music information
Number of subjects: 146
Study: 21330095

Group type: EXPERIMENTAL
Intervention: Topical methadone (10-45 mg/day as powder dissolved in ethoxydiglycol added to PLO)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral methadone (15-40 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (topically administered)
Number of subjects: 16
Study: 19297556

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intravenous pulse cyclophosphamide (IVCY)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 42
Study: 17112875

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 95
Study: 15025555

Group type: EXPERIMENTAL
Intervention: Aprepitant (125mg day 1, 80mg once daily on days 2 and 3 or 2-5) plus standard therapy (intravenous ondansetron and oral dexamethasone)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Standard therapy plus placebo
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Aprepitant plus standard therapy
Number of subjects: 3